Adial Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
Adial Pharmaceuticals, Inc. (ADIL) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $90.53 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-20.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2020-03-20
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-12-31 was -$428.44K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was $150.39K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-06-30 was $297.36K, a 361.40% increase year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-03-31 was $71.22K, a 5.43% decline year-over-year.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2019 was $90.53K.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was -$190.54K, a 158.66% decline from fiscal 2017.
- Adial Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $324.82K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2019-12-31 | -$428.44K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -$278.05K derived: sum of 2 quarters · filed 2020-03-20 | $19.32K derived: sum of 3 quarters · filed 2020-03-20 | $90.53K 10-K · filed 2020-03-20 | |
| 2019-09-30 | $150.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $447.75K derived: sum of 2 quarters · filed 2019-11-14 | $518.97K 10-Q · filed 2019-11-14 | $406.45K derived: sum of 4 quarters · filed 2020-03-20 | |
| 2019-06-30 | $297.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $368.58K 10-Q · filed 2019-08-13 | $256.06K derived: sum of 3 quarters · filed 2020-03-20 | $38.28K derived: sum of 4 quarters · filed 2020-03-20 | |
| 2019-03-31 | $71.22K 10-Q · filed 2019-05-13 | -$41.30K derived: sum of 2 quarters · filed 2020-03-20 | -$259.08K derived: sum of 3 quarters · filed 2020-03-20 | -$194.63K derived: sum of 4 quarters · filed 2020-03-20 | |
| 2018-12-31 | -$112.52K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-20 | -$330.30K derived: sum of 2 quarters · filed 2020-03-20 | -$265.85K derived: sum of 3 quarters · filed 2020-03-20 | -$190.54K 10-K · filed 2020-03-20 | -$34.81K 10-K · filed 2019-02-19 |
| 2018-09-30 | -$217.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | -$153.33K derived: sum of 2 quarters · filed 2019-11-14 | -$78.02K 10-Q · filed 2019-11-14 | $66.11K derived: sum of 4 quarters · filed 2019-11-14 | |
| 2018-06-30 | $64.45K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $139.75K 10-Q · filed 2019-08-13 | $283.88K derived: sum of 3 quarters · filed 2019-08-13 | $320.62K derived: sum of 4 quarters · filed 2019-08-13 | |
| 2018-03-31 | $75.31K 10-Q · filed 2019-05-13 | $219.44K derived: sum of 2 quarters · filed 2019-05-13 | $256.17K derived: sum of 3 quarters · filed 2019-05-13 | ||
| 2017-12-31 | $144.13K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $180.87K derived: sum of 2 quarters · filed 2019-02-19 | $324.82K 10-K · filed 2019-02-19 | ||
| 2017-09-30 | $36.73K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $180.69K 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | $143.95K 10-Q · filed 2018-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |